| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg | |||
| 500mg | |||
| Other Sizes |
| Targets |
Phytolaccagenin does not have a single defined biological target. It exhibits antifungal activity against ATCC standard cultures of Candida albicans and Cryptococcus neoformans, and against clinical isolates of these fungi. It also shows inhibitory effects on lipopolysaccharide-induced NO production and haemolytic activities. It has anti-inflammatory activity.
|
|---|---|
| ln Vitro |
Phytolaccagenin demonstrates antifungal activity in vitro against ATCC standard cultures of Candida albicans and Cryptococcus neoformans, as well as against clinical isolates of these fungi. It also shows inhibitory effects on lipopolysaccharide-induced NO production and haemolytic activities. Its anti-inflammatory activity has been characterized in cell-based assays measuring NO production and cytokine release.
|
| ln Vivo |
Phytolaccagenin has been studied in vivo for its antifungal and anti-inflammatory activities. It exhibits low toxicity, making it a promising natural compound for therapeutic applications. It has been studied for its potential use in treating fungal infections and inflammatory conditions. Detailed in vivo efficacy data are available in the literature.
|
| Enzyme Assay |
Phytolaccagenin does not have established receptor binding assay protocols. Its antifungal activity is assessed by standard antimicrobial susceptibility testing methods (broth microdilution or agar diffusion). Anti-inflammatory activity is assessed by measuring NO production in LPS-stimulated macrophages. Physical properties: molecular weight 532.71 g/mol; molecular formula C31H48O7. No specific biochemical assay protocols are applicable.
|
| Cell Assay |
Cellular activity of Phytolaccagenin is evaluated in macrophage cell lines (e.g., RAW 264.7) for anti-inflammatory studies. Cells are cultured in appropriate media at 37°C with 5% CO2 and treated with Phytolaccagenin at various concentrations (1-100 µM), then stimulated with lipopolysaccharide (LPS). NO production is measured using the Griess assay. Cytokine levels (TNF-α, IL-6) are measured by ELISA. Cell viability is assessed using MTT or LDH assays. For antifungal studies, standard broth microdilution assays are performed using fungal cultures.
|
| Animal Protocol |
In vivo efficacy is evaluated in animal models of fungal infection or inflammation. Phytolaccagenin is administered orally or intraperitoneally at doses determined by preclinical studies. For antifungal studies, fungal burden is quantified in infected tissues. For anti-inflammatory studies, inflammatory markers are measured in serum and tissue. Sample sizes typically range from 6-10 animals per group. Detailed protocols are available in the literature.
|
| ADME/Pharmacokinetics |
Phytolaccagenin has a molecular weight of 532.71 g/mol and a molecular formula of C31H48O7. Chemical name: (2S,4aR,6aS,6bR,8aR,9R,10R,11S,12aR,12bR,14bS)-8a,12b,14b-trihydrogenio-10,11-dihydroxy-9-(hydroxymethyl)-2-(methoxycarbonyl)-2,6a,6b,9,12a-pentamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylate. It is a triterpenoid compound.
|
| Toxicity/Toxicokinetics |
Phytolaccagenin exhibits low toxicity, making it a promising natural compound for therapeutic applications. Standard toxicology studies would include acute and subchronic toxicity in rodents, genotoxicity screening, and evaluation of effects on vital organs. No clinical trials have been reported for this compound.
|
| References | |
| Additional Infomation |
Phytolaccagenin is a triterpenoid compound. It has been reported to exist in twelve species of pokeweed, American pokeweed, and other organisms with relevant data.
Phytolaccagenin is also known as Jaligonic acid 30-methyl ester. It is a triterpenoid saponin that is the active component of the plant tongue root (Phytolacca spp.). It possesses antifungal and anti-inflammatory activities. It is listed under pesticide standards for analytical research and quality control. No clinical trials or regulatory approvals as a drug have been reported. |
| Molecular Formula |
C31H48O7
|
|---|---|
| Molecular Weight |
532.71
|
| Exact Mass |
532.34
|
| CAS # |
1802-12-6
|
| PubChem CID |
21594228
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
639.6±55.0 °C at 760 mmHg
|
| Flash Point |
199.3±25.0 °C
|
| Vapour Pressure |
0.0±4.3 mmHg at 25°C
|
| Index of Refraction |
1.582
|
| LogP |
5.24
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
38
|
| Complexity |
1050
|
| Defined Atom Stereocenter Count |
11
|
| SMILES |
C[C@@]1(CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(C[C@@H]([C@@H]([C@@]5(C)CO)O)O)C)C)[C@@H]2C1)C)C(=O)O)C(=O)OC
|
| InChi Key |
CYJWWQALTIKOAG-FLORRLIPSA-N
|
| InChi Code |
InChI=1S/C31H48O7/c1-26(25(37)38-6)11-13-31(24(35)36)14-12-29(4)18(19(31)15-26)7-8-22-27(2)16-20(33)23(34)28(3,17-32)21(27)9-10-30(22,29)5/h7,19-23,32-34H,8-17H2,1-6H3,(H,35,36)/t19-,20-,21+,22+,23-,26-,27-,28-,29+,30+,31-/m0/s1
|
| Chemical Name |
(2S,4aR,6aR,6aS,6bR,8aR,9R,10R,11S,12aR,14bS)-10,11-dihydroxy-9-(hydroxymethyl)-2-methoxycarbonyl-2,6a,6b,9,12a-pentamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
|
| Synonyms |
NSC-116453; NSC 116453; Phytolaccagenin
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~50 mg/mL (~93.86 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.69 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8772 mL | 9.3860 mL | 18.7719 mL | |
| 5 mM | 0.3754 mL | 1.8772 mL | 3.7544 mL | |
| 10 mM | 0.1877 mL | 0.9386 mL | 1.8772 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
